Snehal Patel
Surgical · New York, NYNPI 1417286345
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 34.1% of the total.
Across 19 payments — averaging $22.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$149
- Atricure, Inc.$123
- AstraZeneca$46
- Abiomed$29
- Abbott$23
- Johnson & Johnson$20
- plus $46 from 3 others
Across 1 payment — averaging $3650.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$4K
What the payments were for
- Food & beverage$437100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $149 |
| Atricure, Inc. | 3 | $123 |
| AstraZeneca | 2 | $46 |
| Abiomed | 1 | $29 |
| Abbott | 1 | $23 |
| Johnson & Johnson | 1 | $20 |
| Pfizer | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $15 |
How this compares
$437 in reported general payments places this provider in the 55th percentile of 1,544 surgical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 22 | $140 |
| Pantoprazole Sodium | 26 | $135 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 14 | $85 |
| ClopidogrelClopidogrel Bisulfate | 11 | $81 |
| Atorvastatin Calcium | 17 | $76 |
| Oxycodone Hcl | 11 | $34 |
| Furosemide | 21 | $15 |
Paid to pharmacies, not to this prescriber.
Other surgical in New York
- Nicole FeinNew York$225K
- Kenneth RuizNew York$93K
- Terry LinNew York$70K
- James DoolittleNew York$46K
- Irina KommNew York$39K
- Catherine ChoyNew York$24K
- Marianne PistilliNew York$21K
- Ami DalalNew York$16K
- Christopher PrezzanoNew York$14K
- Scott SchneiderNew York$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.